IP Library Granted Patent US 9,809,804
Granted Patent B2
US 9,809,804 · App. 14/762,791 · Granted Nov 7, 2017

Materials and methods for characterizing and using KASIII for production of bi-functional fatty acids

Inventors: Shivani Garg (Ames, IA); Huanan Jin (Wuhan, CN); Marna Yandeau-Nelson (Ames, IA); Basil J. Nikolau (Ames, IA)
Assignee: IOWA STATE UNIVERSITY RESEARCH FOUNDATION, INC.
C12N9/1029C12P7/6409C12Q1/48C12Y203/0118G01N2333/91057
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,809,804
App. No.
14/762,791
Granted
Nov 7, 2017
Kind
B2
Abstract

A mutant Bacillus subtilis , which does not express a functional KASIIIA and/or KASIIIB, and method of making; a mutant Rhodospirillum rubrum , which does not express a functional PhaC1, PhaC2, and/or PhaC3, and method of making; method of characterizing substrate specificity of KASIII; method of making mutant KASIII with altered substrate specificity and/or altered level of activity and nucleic acid, vector, host cell/organism, and mutant KASIII; an in vitro, high-throughput spectrophotometric method of assaying KASIII activity; and materials and methods for using KASIII for production of bi-functional fatty acids and the materials so produced.

Claims (8)

1. A method of characterizing substrate specificity of a 3-ketoacyl-acyl carrier protein (ACP) synthase III (KASIII), which method comprises expressing the KASIII, which is not expressed in wild-type Bacillus subtilis , in a mutant B. subtilis , which does not express a functional KASIIIA and does not express a functional KASIIIB, and wherein the KASIIIB of SEQ ID NO:66 comprises a mutation of Trp221 and a mutation of Val226, and assessing the production of co-functionalized fatty acids, whereupon the substrate specificity of a KASIII is characterized.

2. The method of claim 1 , wherein the KASIII is derived from an organism, the wild-type of which produces ω-functionalized fatty acids.

3. The method of claim 1 , wherein the mutation of Trp221 is Trp221Val and the mutation of Val226 is Val226Leu.

4. The method of claim 1 , wherein the KASIIIA of SEQ ID NO:64 comprises a mutation of Met213, alone or in further combination with Phe208.

5. The method of claim 4 , wherein the mutation of Met213 is Met213Len and the mutation of Phe208 is Phe208Val.

6. The method of claim 1 , wherein the ω-functionalized fatty acids include fatty acids with a hydroxyl-containing group, a benzoyl group, a nitrogen-containing group, or a halogen-containing group at the ω end of the fatty acid.

7. The method of claim 6 , wherein the nitrogen-containing group is an amino-containing group.

8. The method of claim 7 , wherein the amino-containing group is an amino-carboxylic acid.

Continuity (2)
Provisional Application 61755946 · Jan 23, 2013
Related Publication 20160090576A1 · Mar 31, 2016